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Abstract. 
 
Considerable evidence links urokinase plas-
minogen activator (uPA) bound to its surface receptor 
(uPAR) with enhanced invasiveness of cancer cells. By 
blocking uPAR expression in human epidermoid carci-
noma cells (HEp3), we have now identified an addi-
tional and novel in vivo function for this receptor by 
showing that receptor-deficient cells enter a state of 
dormancy reminiscent of that observed in human can-
cer metastasis. Its main characteristic is survival with-
out signs of progressive growth. Five clones transfected 
with a vector expressing uPAR antisense RNA under 
the 
 
b
 
-actin promoter were isolated and shown to have 
uPAR (at the mRNA and protein levels) reduced by 50 
to 80%; four clones, transfected with vector alone and 
having uPAR levels similar to those of parental cells, 
served as controls. In confirmation of our previous re-
sults, reduced uPAR always coincided with a signifi-
cantly reduced invasiveness. Each of the control clones 
produced rapidly growing, highly metastatic tumors 
within 2 wk of inoculation on chorioallantoic mem-
branes (CAMs) of chick embryos. In contrast, each of 
the clones with low surface uPAR, whose proliferation 
rate in culture was indistinguishable from controls, re-
mained dormant for up to 5 mo when inoculated on 
CAMs. Thus, the reduction in uPAR altered the phe-
notype of HEp3 tumor cells from tumorigenic to dor-
mant. Although protracted, tumor dormancy was not 
permanent since in spite of maintaining low uPAR lev-
els, each of the in vivo–passaged antisense clones even-
tually reemerged from dormancy to initiate progressive 
growth and to form metastases at a level of 20 to 90% 
of that of fully malignant control. This observation sug-
gested that other factors, whose expression is depen-
dent on cumulative and prolonged in vivo effects, can 
compensate for the lack of a full complement of surface 
uPAR required for the expression of malignant proper-
ties. These “reemerged,” uPAR-deficient clones were 
easily distinguishable from the vector-transfected con-
trols by the fact that after only 1 wk in culture, the inva-
sion of CAM by all five clones and tumorigenicity of 
four of the five clones were reduced back to the values 
observed before in vivo maintenance. In contrast, dis-
sociated and in vitro–grown cells of control tumors 
were fully invasive and produced large, metastatic tu-
mors when reinoculated on CAMs. Quantitation of the 
percent of apoptotic and S-phase cells in vivo, in the 
control and uPAR-deficient, dormant clones, showed 
that the mechanism responsible for the dormancy was a 
diminished proliferation.
 
U
 
rokinase-type
 
 plasminogen activator (uPA)
 
1
 
 in-
teracts with a specific plasma membrane receptor
that focuses uPA proteolytic activity on the cell
surface (Vassalli et al., 1985; Plow et al., 1986; Roldan et al.,
1990; Blasi, 1993). This interaction facilitates activation of
surface-bound plasminogen by lowering the 
 
K
 
m
 
 of this re-
action 
 
z
 
40-fold (Ellis et al., 1991). In addition, surface-
bound plasmin generated by this interaction is believed to
be at least partially shielded from inhibition by native,
high molecular–weight plasma inhibitors (Plow et al.,
1986; Stephens et al., 1989). Extensive experimental evi-
dence implicates surface-bound uPA in matrix degrada-
tion and invasion in vitro and in vivo (Dano et al., 1985;
Mignatti et al., 1986; Ossowski, 1988; Cajot et al., 1989;
Schlechte et al., 1989; Testa and Quigley, 1990; Ossowski
et al., 1991; Mignatti and Rifkin, 1993; Blasi, 1993; Stahl
and Mueller, 1994) as well as in lung colonization and
spontaneous metastasis (Ossowski and Reich, 1983; Hear-
ing et al., 1988; Axelrod et al., 1989; Crowley et al., 1993;
Kobayashi et al., 1994). It appears that when the uPA pro-
duction is limiting, the enzyme is most efficiently used
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1. 
 
Abbreviations used in this paper
 
: CAM, chorioallantoic membrane;
HEp3, human epidermoid carcinoma; IUdR and BUdR, iododeoxyuri-
dine and bromodexoyuridine; uPA, urokinase plasminogen activator;
uPAR, uPA receptor.
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when receptor-bound (Ossowski, 1988; Ossowski et al.,
1991; Quax et al., 1991). Therefore, when surface-bound,
because of more efficient generation of inhibitor- “resis-
tant” plasmin, lesser activity is required than is required in
the absence of receptor. Immunocytochemical, and in
some cases, in situ hybridization analyses of human cancer
tissue sections indicate that most types of malignant tu-
mors acquire uPA through either auto- or paracrine inter-
actions (DeBruin et al., 1987; Janicke et al., 1990; Duffy et al.,
1990; Grondahl-Hansen et al., 1991). Similarly, the in vivo
expression of uPA receptor (uPAR) has been shown in
many tumors (Pyke et al., 1991; Bianchi et al., 1994; Carri-
ero et al., 1994). The prevalence of surface-bound uPA in
cancer and the experimental results implicating uPA in
this disease suggest that surface proteolysis may represent
a potentially attractive target for directed therapy either
through inhibition of surface uPA activity or by antago-
nists competing for uPA binding to its receptor.
In our previous work (Kook et al., 1994), we targeted
the surface uPAR expression in highly malignant human
carcinoma cells (HEp3) for inhibition by a genetic (anti-
sense) approach. A 5
 
9
 
 fragment of the uPAR-cDNA was
subcloned into a mammalian expression vector in anti-
sense orientation. Transfected clones were isolated, of
which only one had uPAR reduced by more than 70%.
Compared to control, the invasive ability of this clone,
measured in the modified chorioallantoic membrane (CAM)
assay (Ossowski, 1988), was reduced by 
 
z
 
70%. Moreover,
in vivo this clone did not form CAM tumors for as long as
10 wk (the duration of the experiment), while in nude
mice, the initiation of growth followed extended latency
and coincided with the reexpression of a full complement
of uPAR. It is well established that a large proportion of
cancer patients have, at the time of diagnosis, clinically un-
detected disseminated disease, which becomes evident of-
ten many years later. This quiescent state, in which cancer
cells persist but do not manifest themselves clinically, is
operationally defined as dormancy. Our preliminary obser-
vations with the uPAR-deficient clones suggested that, if
confirmed, they may reveal a novel mechanism of cancer
dormancy. Also, it was tantalizing to consider the possibil-
ity of permanent growth arrest of these small cancer foci
(dormant metastases) by therapeutic intervention aimed
at reduction of cell surface uPAR. The HEp3 clone with
reduced uPAR level provided the first cue that such inter-
vention may be possible (Kook et al., 1994). In this clone,
a permanent suppression of tumor growth either persisted
for a long time or was interrupted when uPAR level
rose—most likely because of the inactivation of the viral
promoter directing the transcription of the antisense
RNA—to that of control level. These results hinted at the
possibility that dormancy may be permanent for as long as
uPAR reduction is sustained. To explore this possibility,
we prepared new transfectants using a mammalian (
 
b
 
-actin)
rather than a viral promoter, which was shown to be highly
efficient in expressing the EGF receptor antisense RNA in
epithelial cells (Moroni et al., 1992). We used the anti-
sense-expressing cells to test whether sustained, low
uPAR level can lead to a permanent state of tumor dor-
mancy and, if so, to identify the mechanism responsible for
this effect. The results of these studies provided evidence
that dormancy is tightly linked to uPAR deficit, but they
 
also showed that this deficit can be bypassed, and dor-
mancy interrupted, after protracted in vivo survival. Iden-
tifying and inhibiting the functions responsible for the
compensatory mechanisms may, in combination with anti-
uPAR effects, have important future implications for ther-
apy of occult metastasis.
 
Materials and Methods
 
Materials
 
Materials were obtained from the following suppliers: tissue culture me-
dium, glutamine, and antibiotics, Gibco Laboratories (Grand Island, NY);
trypsin, ICN Pharmaceuticals, Inc. (Costa Mesa, CA); collagenase type
1A and BSA, Sigma Chemical Co. (St. Louis, MO); FBS, JRH Biosciences
(Lenexa, KS); Pro-uPA was a gift from Dr. J. Henkin, Abbott Laborato-
ries (Abbott Park, IL); 
 
125
 
NaI, New England Nuclear (Boston, MA); plas-
min substrate (Spectrozyme PL), American Diagnostica (Greenwich,
CT); COFAL-negative embryonated eggs, Specific Pathogen-Free Avian-
Supply (SPAFAS) (Norwich, CT). Tumor cells (HEp3) are from human
epidermoid carcinoma (Toolan, 1954).
 
Preparation of Constructs
 
A 296-bp uPAR-cDNA fragment (
 
2
 
46 to 250) was PCR amplified using
the following synthetic primers: sense 5
 
9
 
 AT
 
G GAT CC
 
A GAG AAG
ACG TGC AGG GAG CTG, (BamHI restriction site in bold) and anti-
sense 5
 
9
 
 AGG CTG GT
 
A AGC TT
 
C AAG CCA GTC CGA TAG (Hind-
III restriction site in bold). The amplified cDNA fragment was subcloned
into BamHI- and HindIII-digested pLK444 vector (Gunning et al., 1987)
in antisense orientation. Sequence analysis of the fragment showed 100%
homology with the published uPAR sequence (Roldan et al., 1990). The
plasmid containing uPAR-cDNA in antisense orientation, under the 
 
b
 
-actin
promoter, was designated pLKAS. pLKAS and pLK444 were grown in
 
Escherichia Coli
 
 XL-1 blue and the plasmids purified using Qiagen plas-
mid kit (Chatsworth, CA).
 
Transfection and Selection of
Antisense-expressing Clones
 
Human epidermoid carcinoma HEp3 cells obtained from tumors main-
tained on the chorioallantoic membrane were dissociated with collagenase
and plated at high density in DME with 10% FBS. After one in vitro pas-
sage, the cells were plated at 1.3 
 
3
 
 10
 
6
 
 cells per 60-mm dish, and when al-
most confluent, they were transfected with 5 
 
m
 
g of pLK444 or pLKAS
DNA using Lipofectin (Gibco Laboratories) in Opti-MEM medium ac-
cording to manufacturer protocol. The medium was changed 18 h later to
DME with 400 
 
m
 
g/ml of G418, and the cells were passaged when conflu-
ent. When most cells died, the DME was replaced with RPMI with 10%
FBS with G418. 20 control and 34 antisense clones were examined for
binding of 
 
125
 
I-labeled pro-uPA. Antisense clones showing 
 
.
 
50% inhibi-
tion of binding were selected for further testing.
 
Determination of Receptor Numbers
 
Recombinant pro-uPA (Abbott Laboratories) was iodinated to a specific
activity of 
 
z
 
1 
 
3
 
 10
 
7
 
 cpm/
 
m
 
g protein using IodoGen. The methods used
were as described (Ossowski et al., 1991). Briefly, cells (1.5 
 
3
 
 10
 
5
 
 per well)
in a 24-well tray were stripped of endogenous uPA (Stopelli et al., 1986)
and incubated for 60 min at 4
 
8
 
C with 1.5 
 
3
 
 10
 
5
 
 cpm (1 nM) of radioactive
pro-uPA diluted in DME with 1 mg/ml BSA and 20 mM Hepes. Nonspe-
cific binding was obtained by incubating cells with a 20-fold excess of unla-
beled pro-uPA. Cells were washed three times, and the associated radio-
activity was measured in a gamma counter. Clones that showed reduced
binding were tested again using serial dilutions of the labeled pro-uPA,
and Scatchard analysis was performed to determine receptor number and
the 
 
K
 
d
 
 of uPA binding.
 
Plasminogen Activator Measurements
 
Released uPA was collected by incubating cells in serum-free DME for 24
h. Cell-associated uPA was obtained by lysis of cells in 0.1% Triton X-100
in 0.1 M Tris, pH 8.1. Samples were tested in a plasminogen activation as- 
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say using chromogenic substrate for plasmin as described (Mira-y-Lopez
and Ossowski, 1987) and compared to values obtained from a standard
curve generated with dilutions (0.1–20.0 U/ml) of purified uPA. The activ-
ity shown represents uPA secreted and cell associated from 10
 
6
 
 cells over
a period of 24 h.
 
In Vitro Proliferation Rate of Control and
Antisense Clones
 
Cells (8 
 
3
 
 10
 
4
 
 per 35-mm dish) were plated in DME with 10% FBS and in-
cubated for 4 d. Medium was changed after 48 h. Each day, cells in two
dishes were trypsinized and counted. Growth rate of the control and anti-
sense clones was compared in 1 and 0.2% serum and at fourfold lower
plating.
 
Northern Blot Analysis
 
Total RNA was extracted from 
 
z
 
1 
 
3
 
 10
 
7
 
 cells with the Ultraspec RNA
isolation system (Biotecx Laboratories Inc., Houston, TX). 30 
 
m
 
g of RNA
was electrophoresed on 1% agarose gel containing formaldehyde, trans-
ferred to Hybond nylon membrane (Amersham Life Science, Bucking-
hamshire, England) and cross-linked by UV light. The membrane was hy-
bridized with a 1.4-kb uPAR-cDNA probe labeled with [
 
32
 
P]dCTP using
DECA prime II random priming DNA labeling kit from Ambion Inc.
(Austin, TX). After stripping, the membrane was reprobed with glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH-cDNA). The bands were
scanned by laser densitometer, and the results were expressed as arbitrary
units of uPAR per unit of GAPDH.
 
Southern Blot
 
Genomic DNA was extracted using QuickClean DNA extraction system
from Oncogene Research Products (Cambridge, MA), and 10 
 
m
 
g of each
sample was digested with HindIII at 37
 
8
 
C overnight. The samples were
electrophoresed on 0.8% agarose, transferred to a nylon membrane, and
probed with a 1-kb neo gene cDNA fragment labeled with [
 
32
 
P]dCTP.
 
Quantitation of Tumor Cell Invasion on Modified CAM
 
The method used was essentially as described previously (Ossowski, 1988).
Tumor cells were labeled in culture with 0.2 
 
m
 
Ci/ml of 
 
125
 
I-UdR (iodode-
oxyuridine) in DME with 5% FBS for 24 h. The specific activity ranged
from 0.05 to 0.1 cpm/cell. The cells were washed extensively, and 3 
 
3
 
 10
 
5
 
cells in 50 
 
m
 
l PBS were inoculated onto “resealed” CAMs of 10-d-old
chick embryos. After 24 h, noninvading cells were released by trypsiniza-
tion, and the CAMs were counted in a gamma counter to estimate the
number of invasive cells (Ossowski, 1988).
 
Growth of Tumor Cells on CAMs
 
Each CAM was inoculated with 5 
 
3
 
 10
 
5
 
 tumor cells obtained by trypsiniz-
ing cultured control and antisense clones. After 1 wk of incubation, the
nodule formed at the site of cell inoculation was excised, weighed, minced,
inspected microscopically for presence of tumor cells, and reinoculated on
a fresh CAM. When tumors were large (as was the case for control cells),
only part of the mince was used for inoculation. With small nodules, the
entire mince was serially passaged from CAM to CAM. When antisense
tumors showed progressive growth, (between 4 and 5 mo in vivo), they
were dissected, minced, digested with collagenase, and plated in culture for
1 wk and used to determine receptor numbers, invasion, and metastasis.
 
Metastasis Assay
 
Cells for inoculation were prepared as described above, detached with
trypsin, and inoculated (2.5 
 
3
 
 10
 
5
 
 cells per CAM) onto two 10-d-old chick
embryos. After 1 wk of growth on CAMs, the tumors were excised,
weighed, lysed in 500 
 
m
 
l of Tris-Triton, and used for uPA determination.
Lungs of tumor-bearing chick embryos were dissected, minced, and rein-
oculated onto fresh CAMs of 10-d-old chick embryos. 1 wk later, the nod-
ules produced by the lung mince were excised, minced, and inspected mi-
croscopically for the presence of tumor cells. At least 10 fields (at 100
 
3
 
magnification) were inspected and the number of tumor cells per field was
recorded on a semiquantitative scale from “
 
2
 
” to “4
 
1
 
”, where 4
 
1
 
 repre-
sented mainly tumor cells. (The tumor cells are much larger than chicken
cells and therefore are easily detectable.) If no tumor cells were detected,
the mince received a designation of “
 
2
 
”; single tumor cells in most fields,
“1
 
1
 
”; 2–10 tumor cells in most fields, “2
 
1
 
”; 
 
,
 
50% per field tumor cells,
“3
 
1
 
”; and majority tumor cells, “4
 
1
 
”. The tissue was collected, lysed, and
tested for tumor uPA activity. Lungs from uninoculated embryos grown
on CAM for the same period of time served as negative controls. We de-
termined previously (Ossowski and Reich, 1983) that secondary lung nod-
ules containing 1 
 
3
 
 10
 
5
 
 metastatic HEp3 cells and designated as 4
 
1
 
 pro-
duce 
 
z
 
1 Ploug U/mg of protein of human uPA when tested in the plasmin
chromogenic assay, and that a high degree of correlation exists between
metastatic tumor cell count in collagenase-dissociated CAM lung nodules
and the level of human uPA (Ossowski and Reich, 1983). This correlation
was independently confirmed by another group (Brooks et al., 1993). The
human uPA values of CAM lung nodules in Fig. 7 and in Tables III and
IV were determined by the chromogenic assay, and the number of meta-
static cells was calculated from these values.
 
Quantitation of Necrotic and Apoptotic Cells in
CAM Tumors
 
Tumors were excised, minced finely, and dissociated into single cell sus-
pension using collagenase. Cells were mixed with acridine orange and
ethidium bromide at a final concentration of 15 
 
m
 
g/ml each and examined
using a fluorescent microscope at a blue excitation range with a 520-nm
barrier filter as described (Huang et al., 1995). Live and dead cells take up
acridine orange; it intercalates with DNA making it appear green and
binds to RNA, staining it orange. Ethidium bromide is taken up only by
nonviable cells; it intercalates to DNA making it appear orange. At least
400 cells were counted for each sample and assigned to the following cate-
gories: “live-normal” (green with “normal” green nucleus); “live-apop-
totic” (green with intensely stained dark green or yellowish condensed
chromatin); “dead-necrotic” (orange-red because they are permeable to
ethidium bromide, with intact nuclei); and “dead-apoptotic” (bright or-
ange cytoplasm, sometimes poorly identifiable, with chromatin condensed
into spherical, yellow heterogeneously sized beads).
 
Quantitation of Cells in S-phase (Bromodeoxyuridine 
Incorporation In Vivo)
 
The fact that CAM tumors are difficult to dissociate to single cells, and
that even once dissociated, they easily form aggregates of several cells, ne-
cessitated a direct microscopic evaluation (rather than a FACS
 
®
 
 analysis)
of cells in S-phase. Chick embryos with dormant or growing CAM tumors
were injected intravenously with 2.5 mg bromodeoxyuridine (BUdR) in
50 
 
m
 
l, and the embryos were incubated for 2 h. The tumors were excised
and dissociated, and the cells were fixed, permeabilized, incubated for 30
min with fluorescein-labeled anti-BUdR antibodies, mounted in mounting
medium, and examined. Between 400 and 1,000 cells were examined per
sample, and the percent of cells with clearly fluorescent nuclei was calcu-
lated. The number of DNA-synthesizing cells was determined in the cor-
responding clones grown in culture. For these determinations, the proce-
dure was as described, but only 2.5 
 
m
 
g/ml of BUdR and 1-h incorporation
time were used.
 
Results
 
Isolation and Characterization of HEp3
Cells Transfected with Vectors Expressing uPAR 
Antisense RNA
 
Tumors (HEp3) serially passaged on CAMs of chick em-
bryos were dissociated and transfected with a plasmid vec-
tor, pLK444 (Gunning et al., 1987) DNA, as a control, or
with pLK444, into which a 5
 
9
 
 (
 
2
 
46 to 250) uPAR-cDNA
fragment was subcloned in antisense orientation under the
 
b
 
-actin promoter. The vector also contains a G418 resis-
tance gene under the SV-40 promoter. A total of 34 anti-
sense-transfected clones were isolated and examined for
levels of uPAR by comparing binding of radioactive pro-
uPA (see Materials and Methods) to that of controls. Only
5 of the 34 clones (designated AS 24, 32, 33, 36, and 48), in
which the receptor was reduced by at least 50% either at 
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isolation or after several in vitro passages, were selected
for further study (Tables I and II). Clones isolated from
transfections with vector alone (designated LK 5, 9, 12,
and 25), with receptor numbers differing from that of pa-
rental cells by no more than 20%, were used as positive
controls.
All clones (AS and controls) were tested for construct
integration by Southern blotting using HindIII-digested
genomic DNA probed with a 1-kb fragment of the neo-
cDNA. (There is a unique HindIII site in the vector.) We
found (results not shown) that all controls and all but one
of the antisense clones had one or two detectable bands,
suggesting a single or double integration site. AS 32 had
multiple bands of very high intensity.
The levels of uPAR-mRNA were determined by North-
ern blotting and expressed as uPAR-mRNA units per unit
of GAPDH-mRNA. The uPAR-mRNA in parental HEp3
cells was taken as 100%. Fig. 1 shows that the reduced
uPAR number was coincidental with a reduced (51 to 80%)
uPAR-mRNA level in the antisense clones and that the
relatively constant level of mRNA in the two control clones
tested was comparable to that in the parental HEp3 cells.
Only two clones (AS 32 and 36) had easily detectable anti-
sense RNA bands (results not shown). We and others have
shown that reduction in mRNA level of the targeted gene
is not always proportional to the level of detectable anti-
sense RNA (van der Krol et al., 1988; Kasid et al., 1989;
Neckers et al., 1992; Kook et al., 1994). The reduction in
uPAR remained 50% or better in all the antisense clones
after at least 4 mo in culture (Tables I and II).
The reduced uPAR level did not affect the in vitro
growth potential of these clones. Fig. 2 shows that the cells
 
Table I. Reduction of uPAR Number in Antisense-transfected 
Clones
 
Clones
uPAR number (percent reduction)
At isolation
After passage
in culture
After passage
on CAM
 
AS 24 68 56 68
AS 32 58 64 54
AS 33 69 63 58
AS 36 61 50 63
AS 48 37 58 33
 
Transfected clones at isolation, following 3–4 mo in culture, or after they recovered
tumorigenicity in vivo (the latter tested after 1–3 passages in culture) were plated at
1.5 
 
3
 
 10
 
5
 
 cells per 24-well tray, and the total receptor number (after stripping the en-
dogenous uPA) was determined using radioactive pro-uPA binding and Scatchard
analysis as described in Materials and Methods. LK 12 cells (cultured in vitro or after
growth on CAM) or HEp3 parental cells (both expressing similar receptor numbers)
were included as positive controls in each experiment. Their receptor number varied
between experiments from as low as 4.9 to as high as 7.0 
 
3
 
 10
 
5
 
 sites per cell. Each
determination was done in duplicates (mean is shown).
 
Table II. uPA Activity Produced by uPAR-deficient and 
Control Clones
 
Clones At isolation After passage on CAM
 
AS 24 1.2 1.6
AS 32 1.2 1.3
AS 33 1.2 1.2
AS 36 1.1 1.0
AS 48  1.2 N.T.
LK 12 1.3 1.3
LK 25 1.3 1.3
 
Cells were grown to near confluence, and the cultures were washed. After 24 h of in-
cubation in medium without serum, the conditioned media were collected and the
cells were lysed, and both were used for the determination of uPA activity. 
 
N.T.
 
, not
tested.
Figure 1. Reduction of uPAR-mRNA level in antisense-trans-
fected clones. uPAR-mRNA steady-state levels were determined
in parental HEp3 cells, two control clones, and five uPAR anti-
sense clones by Northern blot hybridization (30 mg total RNA)
using uPAR-cDNA (exposure 6 h) and, after stripping, GAPDH-
cDNA (exposure 1.5 h) as probes. The film was scanned, and the
values were expressed as units of uPAR-mRNA per unit of
GAPDH-mRNA and calculated as percent of uPAR-mRNA in
parental cells.
Figure 2. In vitro growth rate of control and antisense clones.
Cells (8 3 104) were plated in 35-mm dishes, and two dishes of
each clone were trypsinized on four consecutive days and
counted. The results shown are calculated by dividing the total
number of divisions by 4 d of growth. 
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in the three control and five antisense clone cultures dou-
bled approximately once every 24 h. Small differences in
growth rate were observed, but they did not bear a rela-
tion to the level of receptor. No difference in proliferation
was observed even under growth limiting conditions, such
as reduced serum or reduced plating density. Division time
rose to 
 
z
 
66 h at 1% serum, and even more at 0.2%, for
both controls and uPAR-deficient clones (results not shown).
No growth over a period of 5 d was observed when cells
were plated at 2 
 
3
 
 10
 
4
 
 per 35-mm dish. (This is not unex-
pected because HEp3 with full complement of uPAR grow
best when crowded.)
A reduction in uPAR level did not affect the overall
uPA content of these cells. Combined uPA activity (se-
creted and cell-associated) produced by 10
 
6
 
 cells over a pe-
riod of 24 h was in the range of 1.1 to 1.3 Ploug units (Ta-
ble II, 
 
first column
 
) and somewhat higher after a passage
on CAMs (Table II, 
 
second column
 
).
 
Effect of Reduced uPAR on Invasion of CAMs
 
The invasive ability of the antisense clones was compared
to that of control cells by inoculating equal numbers of
 
125
 
I-UdR–labeled cells onto CAMs that were wounded
and allowed to reseal for 24 h before inoculation (Ossow-
ski, 1988). After 24 h of incubation, the number of labeled
invading cells was measured and the invasion calculated as
percent of total recovered tumor cells (see Materials and
Methods). As shown in Fig. 3, while control cell invasion
was 68%, the invasion by clones with reduced uPAR level
was only 24% or less. This highly statistically significant
difference confirms our previous results, which showed
that surface uPA is essential for invasion of CAM and of
dermis when inoculated subcutaneously in nude mice
(Kook et al., 1994).
 
Does Reduction in Surface uPAR Lead to a
Prolonged Dormancy?
 
Previous studies of a single uPAR antisense clone sug-
gested that reduced uPAR expression induced tumor cell
dormancy (Kook et al., 1994) and that permanent dor-
mancy may be possible to achieve provided uPAR reduc-
Figure 3. Invasion of “resealed” CAMs by antisense clones
grown in culture. 125I-UdR–labeled cells (3 3 105 per CAM) de-
rived from individual clones were inoculated each onto eight
CAMs. Before inoculation the CAMs were “wounded” and then
allowed to reseal for 24 h. The median of invasion is shown for
each group. Comparison of groups by analysis of variance (SYS-
TAT) analysis showed a highly statistically significant difference
(P 5 0.000). A post-hoc analysis of each clone versus LK 25 con-
trol showed a value of P 5 0.000, except for AS 32, in which P 5
0.001. Similar results were obtained with control clones (LK 9
and 12) (not shown).
Figure 4. Dormancy of anti-
sense-transfected clones main-
tained in vivo. Cells of indi-
vidual clones (5 3 105 per
CAM) were inoculated on
CAMs of two 10-d-old chick
embryos and incubated for 1
wk, and the resulting nodules
were excised, weighed, minced,
and reinoculated onto two
fresh CAMs. Serial passage
of tumors were discontinued
when their weight exceeded
100 mg. (We observed that
tumors of this size, which
contain mostly live tumor
cells, usually continue pro-
gressive growth). M(2) indi-
cates that lungs of these em-
bryos were tested for
metastases and found to be
negative.The Journal of Cell Biology, Volume 137, 1997 772
tion was sustained. To explore this intriguing but prelim-
inary observation, each of the five newly obtained antisense
and four control clones was inoculated onto CAMs and
maintained by serial weekly passage onto fresh CAMs. Af-
ter the first week of growth, and weekly thereafter, the
CAMs were inspected visually, and the site of inoculation
(a clearly visible small nodule arising in response to
wounding occurring during preparation of the CAM) was
excised. The nodules were weighed, minced, and micro-
scopically inspected for the presence of live tumor cells.
(Tumor cells were always discernible in the mince.) In an-
tisense clones, the entire mince, and in the controls part of
the mince, was reinoculated onto fresh CAMs. Starting
from week 2 on the CAM, each of the control clones pro-
duced progressively growing, large tumors (Fig. 4). In con-
trast, the small nodules produced by the antisense clones
either remained completely static or fluctuated slightly,
without showing a persistent increase in mass, for as long
as 4 to 5 mo (Fig. 4, A–D). One clone (AS 36) initiated
growth after 2 mo (not shown). CAMs were inoculated a
second time with cells from each of the controls and all but
one (AS 33) of the antisense clones and maintained by se-
rial passages for up to 8 wk, yielding essentially the same
results as those shown in Fig. 4 for the initial test period of
growth on CAMs and indicating that inability to grow in
vivo was a reproducible property of the antisense-inhib-
ited cells. Moreover, dormancy was observed already in
the first week on CAM, regardless of the number (as low
as 1 3 105 or as high as 2 3 106) of inoculated, uPAR-
deficient cells (results not shown), suggesting that it was
the interaction with the host and not tumor cell–cell inter-
action that was responsible for the effect.
We conclude that low uPAR expression coincides with a
dramatically lengthened period of cancer dormancy. As
noticed from Fig. 4, although dormancy was sustained for
a long time period, it was not permanent since at 4 to 5 mo
all uPAR-deficient clones regained the ability to grow in
vivo (Fig. 4). Was regrowth linked to reexpression of
uPAR? To answer this, uPAR-mRNA level and pro-uPA
binding were measured in tumors that emerged from dor-
mancy by dissociating and growing the cells for 1 wk in
culture. Fig. 5, A and B, and Table I show that uPAR both
at the mRNA and receptor number levels remained low.
Figure 5. uPAR-mRNA level in cells isolated from reestablished
CAM tumors. (A) CAM tumors were dissociated into single-cell
suspension, plated, and kept in culture for 1–2 wk. Total RNA
was extracted from z1 3 107 cells and analyzed by Northern blot
hybridization exactly as described in the legend to Fig. 1. Film was
exposed for 40 min after hybridization with labeled uPAR-cDNA
and for 20 min after GAPDH probes. (B) Units calculated from a
densitometry scan and expressed as described in the legend to
Fig. 1. Only clones AS 32 and 36 had detectable antisense RNA,
both when grown in culture and after forming CAM tumors. Cir-
cled numbers indicate cells after in vivo growth.
Figure 6. Invasion of “resealed” CAMs by cells isolated from
CAM tumors. Cells isolated from progressively growing CAM tu-
mors (LK 25 control, week 4 in vivo, antisense clones weeks 17 to
22 in vivo) were kept in culture for 1 wk, detached, and inocu-
lated on CAMs resealed for 28 h. Invasion was quantitated as de-
scribed in the legend to Fig. 3. Analysis of variance revealed a sig-
nificant  P  5 0.036 difference between the groups. Circled
numbers indicate cells after in vivo growth.Yu et al. Urokinase Receptor Tumor Dormancy 773
Are Other Functions Reestablished when Dormancy
Is Interrupted?
Since we found that tumorigenicity was reestablished in
spite of low levels of uPAR, we tested whether that also
meant a return to full invasive capacity. Reestablished CAM
tumors were tested for invasive ability on modified CAMs
after 1 wk of growth in vitro. As a general rule, a low level
of uPAR foretold low invasiveness (Fig. 6), and all rees-
tablished clones continued to be less invasive than the con-
trols. A slight increase of invasiveness in cells recovered
from CAMs was detected (compare Figs. 3 and 6), but
when two of the clones (dormant and after reemergence
from dormancy) were compared in the same invasion ex-
periment, no significant differences in invasiveness (P 5
0.9 and 0.3, respectively) were found (results not shown).
We concluded that the fluctuation is due to interexperi-
mental variations and not due to intrinsic differences in-
duced by in vivo conditions. When cells from reemerged
clones, with low uPAR and low invasiveness, were reinoc-
ulated onto fresh CAMs and maintained in vivo for 7 d,
three of five clones produced only very small tumors (see
Table IV), suggesting that the compensatory mecha-
nism(s) that took months of in vivo survival to develop
was quickly extinguished in culture.
Metastatic Potential of Antisense Clones with
Reduced uPAR
The parental cells were shown to be highly metastatic in
chick embryo (Ossowski and Reich, 1983) and in nude mice
(Ossowski et al., 1991). The question remained whether
cells that emerged from the protracted dormancy were
metastatic. Tests for lung metastases throughout the dor-
mancy, and especially in the weeks when some increases in
the CAM nodules were apparent, were negative (Fig. 4, A
and C). However, once growth in vivo became progres-
sive, lung metastasis (measured by the content of human
uPA and confirmed by microscopic analysis of lung minces;
see Materials and Methods) was detected, albeit at ex-
tremely variable levels. Was the variation in metastasis a
true reflection of metastatic potential or simply the result
of reduced “primary” tumor masses? In a fully malignant
control clone (LK 25), the level of lung metastasis was di-
rectly proportional to the tumor mass (Fig. 7). If reemer-
gence from dormancy reestablishes a full metastatic po-
tential, then the expected result would be that tumors of
equal sizes produced by controls and antisense clones
would yield similar levels of lung metastasis. As shown in
Table III, when such comparisons were carried out, the
metastatic potential of some uPAR-deficient clones (AS
24 and 33) was reduced by more than 80%, while in clone
AS 32 it was similar to control. The observed reduced level
of lung metastasis in embryos bearing tumors that re-
emerged from dormancy (Table III) and the even more
dramatic loss of metastatic potential of the same cells rein-
oculated on CAMs after only 1 wk in culture (Table IV)
were not simply due to a reduction in the level of uPA pro-
duced by these cells. First, as stated in Materials and
Methods, uPA analysis of each CAM lung nodule was ac-
companied by microscopic inspection for presence of tu-
mor cells, and the ones with no tumor cells were later found
to have undetectable levels of human uPA. Also, as shown
in Table IV, human uPA activity of “primary” tumors pro-
duced by control or uPAR-deficient cells was similar, mak-
ing lung uPA determination a reliable comparative mea-
sure of metastasis in these tumors. These results show that
a set of functions, which are reexpressed only after a pro-
Figure 7. Dependence of LK 25 metastasis on primary tumor
mass; standard curve. In vivo–grown LK 25 cells were dissoci-
ated, kept in culture for 1 wk, and reinoculated on fresh CAMs.
After 1 wk on CAM, tumors were excised and weighed. The
number of metastatic cells in embryo lungs was measured (see
Materials and Methods). As seen, within the range of 90–270 mg,
metastasis level is directly proportional to the tumor mass. Tu-
mors smaller than 50 mg do not yield easily detectable me-
tastases.
Table III. Metastasis Produced by Antisense Clones That 
Emerged from Dormancy after Serial Passage on CAMs
Clone
Tumor
weight
Metastatic
cells in lung
mince
(microscopy)*
Metastatic cells in lungs (3 1024)
Expected
from standard
curve‡
Measured
(percent of expected)
mg
AS 24CAM-16
§ 110 11 2.1 19.0
AS 32CAM-18 250 31 6.7 89.0
AS 33CAM-17 100 11 1.8 17.0
AS 36CAM-9 180 21 4.9 41.0
AS 48CAM-18 110 11 2.1 71.0
LK 25CAM-3 200 41 6.0 100.0
*Lungs removed from tumor-bearing chick embryos were inoculated on fresh CAMs
and grown for 1 wk, and the nodules were excised, minced, and inspected microscopi-
cally for presence of metastatic cells. (For additional details and scoring, see Materials
and Methods). In each case, the larger of the two (or three) CAM-passaged tumors was
used for analysis.
‡Expected values represent the number of metastatic cells that are expected to be
present in lungs of embryos bearing a given tumor mass. They are obtained by extrap-
olation of a standard curve generated by fully metastatic (LK 25) tumor cells (Fig. 7),
which shows that when the experimental conditions are not altered, metastasis is
strictly proportional to tumor mass. Therefore, if tumors of equal size yield a smaller
number of disseminated cells (such as the case with uPAR-deficient tumors), it indi-
cates a diminished metastatic potential. In each case, the larger of the two (or three)
CAM-passaged tumors was used for analysis.
§The numbers indicate number of weeks on CAM.The Journal of Cell Biology, Volume 137, 1997 774
longed maintenance of low uPAR cell in vivo, can com-
pensate for the lack of uPAR and restore tumorigenicity
in each of the tested clones (and metastasis in some) and
suggest that an additional set of compensatory functions
may be required for the restoration of the metastatic po-
tential. This tentative conclusion is supported by the find-
ings that of the two functions, tumorigenicity appears to be
regained more consistently than metastasis (Fig. 4 and Ta-
ble III) and maintained more efficiently when the cells are
separated from the host (Table IV).
Mechanism(s) Responsible for Tumor Dormancy
Two basic mechanisms can account for the observed in-
ability of the reduced uPAR clones to form progressively
larger masses when inoculated on CAMs: an arrest in cell
proliferation and/or an increased rate of death. We exam-
ined the proportion of live and dead (apoptotic and ne-
crotic) cells in large, progressively growing control (LK
25) tumors, AS 24 tumors in the process of reemergence
from dormancy, and AS 48 dormant tumors. As shown in
Table V, the percent of live cells in all three types of tu-
mors was nearly identical (76%). Also, there was no indi-
cation that uPAR-poor cells were more prone to die by
apoptosis since the percents of apoptotic cells (live and
dead) were 17, 14, and 13 for LK 25, AS 24, and AS 48, re-
spectively. These results show that the uPAR-antisense
clones enter a state of dormancy as a consequence of re-
duced proliferation. To directly test this possibility, tumor-
bearing embryos were injected with BUdR and the per-
cent of tumor cells that incorporated BUdR (S-phase
cells) were counted. As shown in Table VI, the percent of
DNA-synthesizing cells was reduced by more than 60% in
a dormant AS 24 clone, as compared to a vector control
(progressively growing LK 25 tumor). As expected from
the growth curves of clones cultured in vitro (Fig. 2), the
DNA synthesis in vitro (determined by the BUdR incor-
poration method) was similar in the control and the AS 24
cells (Table VI).
Discussion
The results of this study demonstrate that to initiate pro-
gressive tumor growth in vivo, epidermoid carcinoma
(HEp3) cells require a full complement of surface uPAR.
This conclusion is based on the observation, summarized
in Fig. 8, that all control cells (parental and four indepen-
dent control clones transfected with vector alone) with
similarly high uPAR numbers produced actively growing
tumors when inoculated on CAMs. In contrast, all five of
the antisense clones, with receptor levels reduced by more
than 50%, remained dormant for as long as 5 mo in vivo
(Fig. 4). Two additional antisense clones (AS 3 and 26), in
which uPAR was reduced by only 30%, emerged from
dormancy after 6 and 7 wk in vivo, respectively (results not
shown). This high degree of correlation between uPAR
level and tumorigenicity or dormancy, exhibited by 11 in-
dependent clones, establishes a basis for proposing a novel
function for uPAR.
How can a reduction in uPAR block tumorigenicity? Is
it possible that the inability to efficiently degrade the sur-
rounding matrix, due to a reduction in surface proteolysis,
affects proliferation, or are other growth-stimulating or
death-preventing effects mediated via uPAR loss? We
showed previously (Kook et al., 1994), and confirmed in
the current group of antisense clones (Fig. 3), that cells
with low uPAR levels have dramatically (.75%) reduced
invasiveness when tested in a modified CAM assay (Os-
sowski, 1988). This was not unexpected since when pre-
pared for inoculation, the CAM is wounded superficially
and then allowed to reseal. During this process, the CAM
Table IV. Effect of Reduced uPAR on Lung Metastasis of Antisense Clones Inoculated on CAMs as Single Cell Suspensions
Clone
Tumor weight Tumor uPA U/mg protein
Metastatic cells in lungs (3 1024)
Expected
from standard
curve
Measured
(percent of
expected) Mean (SD) Mean (SD)
mg
AS 24 55 (8) 0.9 (0.2) 0.0 0.0
AS 32 260 (114) 0.9 (0.2) 7.4 22.9
AS 33 107 (5) 0.7 (0.2) 2.0 20.0
AS 36 64 (8) 0.6 (0.0) 0.0 0.0
AS 48 44 (12) 0.7 (0.1) 0.0 0.0
LK 25 200 (40) 0.7 (0.0) 6.0 100.0
Cells isolated from the same CAM tumors described in Table III and control tumor (LK 25) were enzymatically dissociated, grown in culture for 1 wk, and inoculated on fresh
CAMs at 2.5 3 105 cells per CAM, on three embryos each. After 1 wk of in vivo incubation, the tumors were weighed, minced, lysed, and used to determine uPA activity. The em-
bryo lungs were tested for metastasis as described in Materials and Methods. Metastasis shown for the largest tumor of the three in each group.
Table V. Proportion of Live and Dead (Necrotic and Apoptotic) 
Cells in Progressively Growing and Dormant CAM Tumors
Tumor
Live cells Dead cells
Normal Apoptotic* Necrotic Apoptotic
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
LK 25 75.7 (8) 12 (5) 6 (2) 5 (2)
AS 24 76.5 (4) 8 (2) 8 (2) 6 (6)
AS 48 76.5 (5) 9 (2) 10 (4) 4 (2)
The assignment of cells to the different groups is based on ethidium bromide and acri-
dine orange staining (see Materials and Methods). Tumors growing on CAM for 4 to
10 passages were excised and weighed. They were 310, 110, and 60 mg, for LK 25,
AS 24, and AS 48, respectively. The numbers given are the means of four determina-
tions. The experiment was repeated with tumors of LK 9, AS 36 (growing), and AS 24
(dormant), which had 78, 83, and 84% live cells, respectively.
*Apoptotic cells with plasma membrane still intact as determined by impermeability
to ethidium bromide.Yu et al. Urokinase Receptor Tumor Dormancy 775
tissue, and especially its wounded surface, becomes highly
enriched in fibroblasts, fibronectin, and collagen, so that to
penetrate this barrier, a tumor must generate sufficient pro-
teolytic activity. Because uPAR has an established role in
the more efficient generation of plasmin and its occupancy
by uPA may be involved in overexpression of additional pro-
teolytic enzymes (Rao et al., 1995), the loss of ability to in-
vade dense tissue, such as a wounded and resealed CAM,
is an expected consequence of reduction in this receptor.
Tumorigenicity (or dormancy), however, is tested in a
wounded CAM that has not been allowed to reseal before
tumor cell inoculation and that, as shown (Ossowski,
1988), was highly susceptible to invasion, even by weakly
invasive cells. Therefore, regardless of their uPAR level,
all cells have a similar chance to access connective tissue
and the blood vessels of the CAM. It is still possible, how-
ever, that the subsequent expansive growth of uPAR-poor
cells may be hindered by the “healing” of CAM, which
may proceed in spite of tumor cell presence by forming a
dense connective tissue around the tumor inoculum.
An alternative explanation for the observed dormancy
of cells with low receptor number may invoke an alter-
ation in tumor cell phenotype either in conjunction or in-
dependently of the reduced surface proteolysis. Low uPAR
may bring about an intrinsic defect resulting in growth ar-
rest or in enhanced susceptibility to cell death. In the latter
case, proliferation may proceed at the same rate, with dor-
mancy achieved through enhanced rate of tumor cell
death. Dramatic reduction in tumor cell mass due to apop-
tosis caused by withdrawal of essential growth factors has
been well documented (Kyprianou and Isaacs, 1988; Vail-
lancourt et al., 1996). It has also been shown that me-
tastases that are “dormant” because of inability to induce
new blood vessel formation (Holmgren et al., 1995) main-
tained their status through a balance between cell prolifer-
ation and apoptosis.
At first glance it may seem that for therapeutic pur-
poses, the mechanisms responsible for dormancy are not
of major importance as long as tumor cell numbers remain
constant (and not expanding). Cycling and dying cells, how-
ever, while susceptible to inhibition by the same agents
that are effective against progressively growing tumors,
are also more prone to accumulating genetic defects. In
contrast, arrest or reduction in the rate of cell cycling may
reduce emergence of new mutants. For this reason, in vivo
models representing both mechanisms need to be estab-
lished. In the case of HEp3, we found that the proportion
of live, intact cells in cell suspensions of tumor produced
by antisense clones at the time of dormancy, during emer-
gence from this condition, and in progressively growing
control tumors was essentially the same (z76%) (Table
V). Also, regardless of the in vivo growth characteristics of
the tumor, the proportion of apoptotic cells (either alive or
dead) was similar. These results clearly indicate that the
inability to grow in vivo cannot be ascribed to enhanced
death of the antisense cells and suggest that uPAR-poor
state is associated with a proliferative defect in vivo. The
results of in vivo incorporation of BUdR support this con-
clusion. Although it is too early to speculate on the mecha-
nism(s) responsible for the growth arrest of antisense
Table VI. Proportion of DNA-synthesizing Cells In Vivo and In 
Vitro (BUdR Incorporation)
Cell type Growth conditions
BUdR positive
(percentage of total
cell number)
LK 25 In culture 41.4
LK 25 On CAM, growing 28.6, 36.4*
AS 24 In culture 38.8
AS 24 On CAM, dormant 11.8, 10.9*
*Numbers are from two independent experiments. BUdR (2.5 mg/embryo, 2.5 mg/ml
of medium) was injected intravenously or added to in vitro cultures, respectively. The
in vivo incorporation was measured 2 h after injection, and the in vitro was measured
1 h after addition to culture medium. BUdR incorporation was quantitated by counting
fluorescein-labeled nuclei after incubation with fluorescein-coupled anti-BUdR anti-
bodies (see Materials and Methods).
Figure 8. Summary of in
vitro and in vivo properties
of control and uPAR anti-
sense clones. Cells of control
clones rapidly form large tu-
mor masses on CAMs (large
open spheres), while cells in
which uPAR is inhibited re-
main dormant in vivo (small
circles) for as long as 5 mo
and then reemerge to form
tumors. However, while the
tumorigenic and metastatic
properties of the control
clones are stable, the com-
pensatory mechanism oper-
ating in vivo and leading to
the interruption of dormancy
produces heterogeneous and
unstable phenotype that
never reaches the full malig-
nant potential of the con-
trols. H, high; I, intermedi-
ate;  L, low.The Journal of Cell Biology, Volume 137, 1997 776
clones, a full complement of surface uPAR may be neces-
sary for generation of growth stimuli either through auto-
crine mechanisms or by inducting stroma into paracrine
interactions. In addition, reduced proteolysis may inter-
fere with activation, or release from matrix, of growth fac-
tors (Saksela and Rifkin, 1990; Mars et al., 1995; Naldini
et al., 1995). Finally, a reduced uPAR may diminish re-
sponses mediated via this receptor, such as migration,
mitogenicity, or induction of neovascularization (Pepper
et al., 1987; Odekon et al., 1992; Rabbani et al., 1992; Busso
et al., 1994). It is also possible that unlike in Lewis lung
carcinoma (Holmgren et al., 1995), a failure to induce new
vessel formation by uPAR-poor HEp3 cells as a result of
inappropriate remodeling of extracellular matrix, rather
than causing their death by apoptosis, may reduce their
proliferation.
Although gathered from a single experimental model,
our results nevertheless clearly show that by targeting
uPAR for reduced expression, a protracted state of tumor
dormancy can be achieved. However, as shown in Fig. 4
and summarized in Fig. 8, each of the antisense clones is
able to interrupt dormancy in spite of sustaining low levels
of uPAR, suggesting that additional factor(s) may com-
pensate for the defect of uPAR-poor cells. It is of obvious
importance to determine whether the interruption of dor-
mancy is achieved always through the same mechanism or,
as possibly suggested by the heterogeneous phenotypes of
the reemerging tumors (Fig. 8), by different compensatory
factors. Our current efforts, which include subtractive hy-
bridization, are aimed at identifying these factors.
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